Respiratory Syncytial Virus Infections research hub
10 indexed studies · 7 currently recruiting
- recruitingTherapeutic confirmatory (Phase III)
A Phase 3b, open-label study to evaluate the non-inferiority of the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in adults 18-49 years of age at increased risk of respiratory syncytial virus disease, compared to older adults ≥60 years of age.
This study is testing a new vaccine for RSV infection in adults aged 18-49 who are at higher risk. It compares how well their immune system responds to the vaccine to how older adults (60+) respond, and checks for any side effects.
Germany - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, open-label, randomized, controlled study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with a COVID-19 mRNA vaccine (Omicron XBB.1.5) in adults aged 50 years and above.
This study is looking at a new vaccine for RSV (a common cold-like virus) in people aged 50 and over. It's testing if it works well and is safe when given at the same time as an updated COVID-19 vaccine.
Spain · Belgium · Netherlands - recruitingPhase III and phase IV (Integrated)
A Phase 3, randomized, controlled, partially blind, immuno-bridging study to evaluate immunogenicity, reactogenicity, safety and the occurrence of RSV-associated respiratory tract illness after administration of a single dose of GSK’s RSVPreF3 OA investigational vaccine in adults aged 60 years and older.
This study is testing a new vaccine for older adults against a common chest infection called RSV. It looks at how well the vaccine works, if it causes side effects, and how safe it is for people aged 60 and over.
Finland · Poland · Spain - recruitingHuman Pharmacology (Phase I)- First administration to humans
A study on the safety of and immune response to different doses of an mRNA vaccine against RSV in healthy adults.
This study is testing a new vaccine to protect against a common chest infection called RSV. Researchers want to see if it's safe and how well it makes your body fight off the virus. It's for healthy adults and is one of the first times it's being given to people.
Spain - active not recruitingPHASE3
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
This study is looking at an RSV vaccine for people aged 60 and over. It aims to find the best time for repeat vaccination, understand long-term protection, and give the vaccine to people who previously received a dummy treatment.
United States · Australia · Belgium - recruitingTherapeutic exploratory (Phase II)
A Phase 2b, randomized, controlled, open-label study to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults (≥18 years of age) when administered to lung and renal transplant recipients comparing 1 versus 2 doses and compared to healthy controls (≥50 years of age) receiving 1 dose
This study is looking at a new vaccine to protect people who have had lung or kidney transplants from a common bug called RSV. We want to see how well the vaccine works and if it's safe, by giving one or two doses and comparing it to healthy people.
Spain · Italy · Germany - recruitingPHASE2
A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant
This study looks at how long an RSV vaccine protects adults aged 18 and over who have had a lung or kidney transplant. It also checks how safe the vaccine is and how well it boosts protection when they get another dose.
United States · Australia · Canada - recruiting
Identification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With RSV
This study looks for clues in adults with severe RSV infection to understand why some people get sicker than others. Researchers will collect samples like nose swabs and blood to find markers that predict illness severity and help improve future treatments for this common winter virus.
France - active not recruitingPHASE3
Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
This study is looking at a new vaccine to protect older adults (60+) from RSV, a common chest infection. We want to see how safe it is, if it causes side effects, and how well it helps your body fight off the virus for up to five years.
United States · Finland · Germany - active not recruiting
RESCEU: Defining the Burden of RSV Disease
This study, called RESCEU, is looking at how RSV affects healthy babies in the UK. Researchers will follow babies for several years to understand how often they get RSV, how severe it is, and the costs involved. This will help improve care for babies with RSV.
United Kingdom